Table 1 Demographic and baseline characteristics

From: A randomized, double-blind, placebo-controlled, phase IIa, clinical study on investigating the efficacy and safety of SPH3127 tablet in patients with essential hypertension

 

Placebo (n = 31)

SPH3127 50 mg (n = 30)

SPH3127 100 mg (n = 30)

SPH3127 200 mg (n = 30)

Gender, n (%)

   Male

20 (64.5)

16 (53.3)

20 (66.7)

20 (66.7)

   Female

11 (35.5)

14 (46.7)

10 (33.3)

10 (33.3)

Age, mean (SD), y

49.3 (9.5)

49.9 (8.2)

48.6 (11.2)

48.0 (9.5)

BMI, mean (SD), kg/m2

26.4 (3.2)

25.8 (3.4)

26.6 (3.5)

26.7 (3.8)

msDBP, mean (SD), mmHg

91.5 (8.8)

89.5 (9.4)

91.6 (9.2)

90.2 (9.6)

msSBP, mean (SD), mmHg

146.7 (7.0)

148.0 (7.2)

147.6 (9.4)

147.4 (5.4)

  1. Continuous variables were denoted as mean (SD); categorical variables were denoted as n (%)
  2. BMI body mass index, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure, SD standard deviation
Back to article page